Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis.
OBJECTIVE
Previously we found a highly significant increase of phosphatidylethanolamines (PE) in response to acute lipoprotein apheresis (LA) with whole blood dextran sulfate adsorption (DSA) in contrast to the overall tendency of reduction of lipid metabolites of all lipid classes in post-apheresis plasma. Therefore, the aim of the present study was to analyze long-term modifications of the plasma lipidomic profile in patients with repeated DSA apheresis.


METHODS
Nine patients weekly treated with DSA were followed for 40 weeks. Pre- and post-apheresis levels of routine lipid parameters and lipidomic profiles of five apheresis sessions were assessed.


RESULTS
The main finding of the present study was a progressive increase of pre- and post-apheresis plasma lysophosphatidylcholine (LPC) levels, which doubled in concentration at the end of the 40 week observation period. LPC metabolites which mainly contributed to this increase were LPC 20:4 > 18:0 > 18:1 > 16:0 > 20:3 > 18:2.


CONCLUSIONS
These data indicate that long-term application of DSA technology may be associated with a continuous increase in LPC levels. Possible pro- or anti-atherogenic consequences should be elucidated in further studies.
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, TU Dresden, Germany. Electronic address: Juergen.Graessler@uniklinikum-dresden.de.
Juergen
J
Graessler
Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.
Kai
K
Schuhmann
Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany.
Andrej
A
Shevchenko
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, TU Dresden, Germany.
Steffi
S
Kopprasch
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, TU Dresden, Germany.
Ryan
R
Ban
Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, TU Dresden, Germany.
Sybille
S
Bergmann
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, TU Dresden, Germany.
Stefan R
SR
Bornstein
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, TU Dresden, Germany.
Bernd
B
Hohenstein
Department of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, TU Dresden, Germany.
Ulrich
U
Julius
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal / Q000379:methods*; D016264:Dextran Sulfate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000175:diagnosis / Q000628:therapy*; D008074:Lipoproteins / Q000097:blood*; D008244:Lysophosphatidylcholines / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
D015415:Biomarkers; D008074:Lipoproteins; D008244:Lysophosphatidylcholines; D016264:Dextran Sulfate
Dextran sulfate adsorption; Lipidomics; Lipoprotein apheresis; Lysophosphatidylcholines